Active Surveillance vs Standard Surgery Post-Neoadjuvant Chemoradiotherapy for Esophageal Cancer
1. Overall survival at 2 years was 74% for active surveillance and 71% for standard surgery. 2. Median disease-free survival...
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy
1. Cooling was found to have a relative risk reduction of 42% and compression had a relative risk reduction of...
Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases
1. Intracranial objective response rate was 51% with ipilimumab plus nivolumab and 20% with nivolumab alone. 2. Treatment-related grade 3...
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
1. Overall objective response rate was 30%, with 1 patient having a complete response. 2. Grade 3-4 treatment-related events occurred...
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1. Invasive disease-free survival occurred in 19.7% of the T-DM1 group and 32.2% in the trastuzumab group, with an HR...
Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade...
Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent HCC
1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1. Median progression-free survival was 9.4 months in the imlunestrant–abemaciclib group vs 5.5 months in the imlunestrant group with HR...
Fosrolapitant/Palonosetron in Chemotherapy-Induced Nausea and Vomiting
1. The complete response rate at the overall phase in cycle 1 was 77.7% vs 78.2% with treatment vs control...
Nivolumab plus Ipilimumab in MSI-High Metastatic Colorectal Cancer
1. Progression-free survival at 12 months was 79% with nivolumab/ipilimumab vs 21% with chemotherapy, and 24-month PFS was 72% and...